Can the CSL share price crack a new, all-time high in 2023?

Two ASX brokers rate CSL shares as a buy today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The CSL share price last hit an all-time high way back in pre-COVID 2020
  • But the ASX 200 healthcare giant has failed to even come close to $342.75 a share in the three-and-a-half years since
  • ASX brokers are generally positive on CSL shares today, but opinions are divided on whether the company can crack another record high in 2023

It's starting to seem like a long time since the CSL Ltd (ASX: CSL) share price cracked a new, all-time record high. Today, this ASX 200 healthcare share is trading at $304.17 (at the time of writing). That is a share price CSL first hit way back in January 2020.

At the time, CSL hitting $300 was big news But it has crossed this proverbial Rubicon so many times since that it is now a non-event. In fact, CSL's last all-time high came in early 2020 as well. On 20 February, the healthcare giant hit an intra-day high of $342.75 a share – what seemed like the latest in a long string of new record highs for the company.

But when it comes to that high watermark, CSL has barely come close in the three-and-a-bit years since:

So is it possible for CSL to regain its former mojo and exceed $342.75 per share in 2023 to a new all-time high?

a climber scales a sheer rock cliff face reaching out for a handhold with foreboding grey clouds gathering in the sky above him.

Image source: Getty Images

Is a new all-time high coming for this ASX 200 healthcare share?

Well, at least one ASX broker certainly thinks so. As my Fool colleague James covered late last month, broker Morgans currently has an add rating on the CSL share price. Although acknowledging CSL had some significant issues during the worst throes of the COVID pandemic, Morgans now anticipates these difficulties are behind the company.

The broker points to increased plasma collections, higher interest in influenza vaccines, and new product development as factors that it sees leading to "double-digit recovery in earnings growth".

Share price wise, Morgans points to CSL's valuation, stating that the "shares [are] offering good value trading around its long-term forward multiple of ~30x".

But Morgans has a 12-month share price target of $337.92 for CSL right now. Although that would represent a pleasing bounce from the current share price, it still falls short of CSL's reining record high.

As such, perhaps investors might be more inclined to follow the projections of another ASX broker in Citi. Citi also rates CSL shares as a buy today. But this broker has an improved share price target of $350 a share. That would of course be a new all-time high for the ASX 200 healthcare veteran.

If we accept these brokers' views, it does seem possible that CSL will close out 2023 with a new record share price under its belt (or at least close to it). But we'll just have to wait and see if Morgans and Citi are on the money, or if CSL spends another year meandering around the $300 a share mark.

CSL share price snapshot

The CSL share price has been a solid performer in 2023 so far, gaining more than 7.8% since the start of the year. The company is also up around 12.4% over both the past 12 and 24 months.

At the current CSL share price, this ASX 200 healthcare giant has a market capitalisation of $145.88 billion, with a dividend yield of 0.95%.

 

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »